GlassScriptPhysician profile
Anna Tartarone
NPI 1639689235
$2,698.95
in general payments reported to CMS, 2019-2025
29 companies · $645 in 2025
The $645 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $408 · 2022: $458 · 2023: $374 · 2024: $814 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $373.41 | 2021-2025 | Verquvo |
| Esperion Therapeutics, INC. | $249.11 | 2021-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $219.25 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.91 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $187.89 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $153.44 | 2024-2025 | Amvuttra |
| Boston Scientific Corporation | $152.98 | 2021-2025 | Watchman Flx, Watchman Access System |
| Lilly USA, LLC | $132.75 | 2022-2025 | Zepbound, Mounjaro |
| Actelion Pharmaceuticals US, INC. | $126.37 | 2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $107.64 | 2021-2025 | Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $96.52 | 2023-2025 | Camzyos |
| Edwards Lifesciences Corporation | $64.31 | 2021-2025 | Sapien 3 Ultra Resilia |
| Bridgebio Pharma, INC. | $63.52 | 2025 | Attruby |
| Abbvie INC. | $60.35 | 2021-2025 | |
| Amarin Pharma, INC. | $54.30 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $47.67 | 2024 | Arcalyst |
| Amgen INC. | $44.06 | 2022-2025 | Repatha |
| Pfizer INC. | $43.76 | 2021 | |
| Daiichi Sankyo INC. | $43.25 | 2022-2023 | Injectafer |
| Exact Sciences Corporation | $41.85 | 2023-2024 | Cologuard Collection Kit |
| Medicomp INC | $36.27 | 2025 | Telepatch Cardiac Monitor |
| Corcept Therapeutics | $33.15 | 2023 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.80 | 2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $26.29 | 2023 | Shingrix |
| Atricure, INC. | $26.24 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $21.15 | 2023 | Inpefa |
| Abbott Laboratories | $20.34 | 2022 | |
| Novo Nordisk INC | $20.15 | 2024 | Rybelsus, Ozempic |
| Dexcom, INC. | $18.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Tartarone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.